Figure 2.

(A) Number of patients receiving dose of OCS (prednisolone equivalent) by category. (B) Median (Q1–Q3) dose of OCS. (C) Percentage reduction in dose of OCS from MIRRA baseline, at exit from the OLE study. *Between the end of the MIRRA treatment period and initiation of OLE, mepolizumab treatment was discontinued for between 8 weeks and 20 months. ^†At OLE entry, two patients were classified as receiving OCS 0 mg/day because of a gap in the reporting of concomitant medication data. Both patients were receiving OCS of ≥5 mg/day and met all necessary eligibility criteria for the OLE. ^‡Study exit is defined as the latest three‐month period before patients either reached study end/completed (coinciding with commercial license of mepolizumab for EGPA in the relevant country) or discontinued treatment early. EGPA, eosinophilic granulomatosis with polyangiitis; OLE, open‐label extension; OCS, oral corticosteroids; Q1, lower quartile; Q3, upper quartile.